Concert Pharmaceuticals
99 Hayden Avenue
Suite 500
Lexington
Massachusetts
02421
United States
Tel: 781-860-0045
Website: http://www.concertpharma.com/
Email: info@concertpharma.com
310 articles about Concert Pharmaceuticals
-
Concert Pharmaceuticals Announces Sale of VX-561 Milestones to Vertex for $32 Million
5/17/2021
Concert Pharmaceuticals, Inc. announced that Vertex Pharmaceuticals Incorporated has purchased the potential future milestones under the companies’ 2017 asset purchase agreement relating to VX-561 for $32 million.
-
Concert Pharmaceuticals Reports First Quarter 2021 Financial Results
5/4/2021
CTP-543 Phase 3 Program for Alopecia Areata Advancing as Planned to Support NDA Filing in Early 2023 Conference Call Scheduled Today at 8:30 a.m. ET
-
Concert Pharmaceuticals to Report First Quarter 2021 Results on May 4, 2021
4/27/2021
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the first quarter of 2021, on Tuesday, May 4, 2021, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its first quarter 2021 financial results and provide a business update.
-
Concert Pharmaceuticals to Present at Upcoming Investor Conferences - Mar 02, 2021
3/2/2021
Concert Pharmaceuticals, Inc. announced that it will present a corporate overview at the following upcoming virtual investor conferences
-
Concert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical Programs
2/25/2021
CTP-543 Phase 3 Program Advancing in Alopecia Areata; THRIVE-AA2, the Second CTP‑543 Phase 3 Trial, to Initiate 1H2021 CTP-543 Long-Term Data Presented at EADV Show Hair Regrowth was Maintained or Improved in Patients with Alopecia Areata, Expanding Previous Phase 2 Results Conference Call and Webcast Scheduled Today at 8:30 a.m. ET
-
Concert Pharmaceuticals to Report Full Year 2020 Results on February 25, 2021
2/18/2021
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2020, on Thursday, February 25, 2021, before the U.S. financial markets open
-
Concert Pharmaceuticals Announces Results from CTP-692 Phase 2 Trial in Patients with Schizophrenia
2/1/2021
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that its Phase 2 clinical trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did not meet the primary endpoint or other secondary endpoints. CTP-692 is a deuterated form of D-serine
-
Concert Pharmaceuticals said its Phase II clinical trial for its adjunctive schizophrenia treatment, CTP-692, did not meet the primary endpoint or other secondary endpoints, causing the company to halt development of the drug.
-
Concert Pharmaceuticals to Present at Upcoming Investor Conferences - Nov 09, 2020
11/9/2020
Concert Pharmaceuticals, Inc. announced that it will participate at the following upcoming investor conferences
-
Clinical Catch-Up: November 2-6
11/9/2020
It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look. -
Concert Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Company Update
11/5/2020
Our focus this year has been to advance our proprietary pipeline. Our team has diligently and effectively executed on our plan, and I’m pleased that we have achieved our stated 2020 pipeline milestones.
-
Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
11/3/2020
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA1, the first Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata.
-
Concert Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 5, 2020
10/29/2020
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020, before the U.S. financial markets open
-
Concert Pharmaceuticals Presents CTP-543 Data from Long-Term Extension Study in Alopecia Areata During Late-Breaking Session at EADV Congress
10/29/2020
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented initial data from the ongoing long-term, open-label extension study of the investigational medicine CTP-543 in patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss. The data from this long-term extension study show that, relative to previous Phase 2 study results of CTP-543, hair regrowth asses
-
Concert Pharmaceuticals Announces Publication on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology
10/22/2020
Concert Pharmaceuticals, Inc. announced that the Journal of Investigative Dermatology published results from a survey designed to understand the burden and everyday experience for patients living with moderate-to-severe alopecia areata.
-
Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress
10/13/2020
Concert Pharmaceuticals, Inc. announced that it will present clinical data on CTP-543 for the treatment of alopecia areata as a late-breaker oral presentation at the 29th European Academy of Dermatology and Venereology Virtual Congress.
-
Concert Pharmaceuticals Completes Enrollment in CTP-692 Phase 2 Trial in Patients with Schizophrenia
9/29/2020
Concert Pharmaceuticals, Inc. announced that it has completed patient enrollment of its Phase 2 clinical trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia.
-
Concert Pharmaceuticals to Present at Upcoming Investor Conferences - Sep 08, 2020
9/8/2020
Concert Pharmaceuticals, Inc. announced that it will participate at the following upcoming virtual investor conferences:.
-
Concert Pharmaceuticals to Present at The JMP Securities CNS Forum
8/18/2020
Concert Pharmaceuticals, Inc. announced that James V. Cassella, Ph.D., Chief Development Officer, will be participating virtually in a fireside chat at The JMP Securities CNS Forum on August 19, 2020, at 10:00 a.m. ET.
-
Concert Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Company Update
8/6/2020
CTP-543 Phase 3 Trial Initiation in Alopecia Areata Expected to Begin Fourth Quarter 2020 CTP-692 Phase 2 Trial Enrollment in Schizophrenia Expected to be Complete by Year-End 2020 Conference Call Scheduled Today at 8:30 a.m. ET LEXINGTON, Mass.--( BUSINESS WIRE )-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2020. “We continue to be committed to advancing both of o